Muscular Dystrophy Association and Catabasis Pharmaceuticals Collaborate on Clinical Study
Catabasis Pharmaceuticals and the Muscular Dystrophy Association (MDA) have announced a partnership that will support Part B of the MoveDMD clinical trial, currently evaluating the effectiveness and safety of Duchenne muscular dystrophy (DMD) treatment candidate CAT-1004 in children. CAT-1004, believed to be a disease modulator regardless of mutation, is…